British Patient Capital
Arnaud Garcon has a diverse work experience spanning various roles and industries. Currently, they are the Senior Investment Manager at British Patient Capital, a subsidiary of the British Business Bank. In this role, they build relationships with fund managers, conducts due diligence, and manages a portfolio of fund investments.
Before their current position, Arnaud served as a Business Manager at Imperagen, Apini Therapeutics, Sentira XR, Complement Therapeutics, and MCR Biofactory. In these roles, they were responsible for various business management tasks.
Arnaud also has extensive experience at the University of Manchester Innovation Factory, where they held several roles. These include Senior Project Manager, IP Development and Partnering Manager, Team Leader of the New Projects Team, and Commercialization Executive. In these positions, they worked on developing commercial opportunities, building business models and plans, managing investments, and fostering innovation and entrepreneurship within the university.
Prior to their time at the University of Manchester, Arnaud worked as a Principal Scientist at Renovo and as a Senior Scientist at Syngenta. In these roles, they contributed to antibody technology development and immuno assays.
Arnaud's work experience began as a Research Associate at the University of Manchester, where they specialized in research.
Overall, Arnaud Garcon has a strong background in business management, investment, commercialization, and scientific research across multiple industries.
Arnaud Garcon completed their Bachelor's degree in Physics and Chemistry at ESPCI Paris - PSL from 1993 to 1997. Following this, they pursued further education and obtained a DEA degree in Pharmacology from Université Paris Cité in 1997-1998. Finally, they completed their doctoral studies at The University of Sheffield from 1997 to 2001, earning a PhD degree in Biological Chemistry.
This person is not in any offices
British Patient Capital
British Patient Capital invests in a diversified portfolio of best-in-class venture and growth capital funds and start ups, capturing value through financing the growth of innovative companies. We invest on a commercial basis to deliver competitive returns and manage risk.As well as providing our own funding we work to encourage more investors tomake allocations to this asset class by demonstrating that a long-term patient capital investment strategy can produce commercially attractive returns.Once we’ve established a strong record, and have proved the value of the asset class, we intend to privatise British Patient Capital at an appropriate time in the future.